GH SecretagoguesResearch OnlyS

Mod GRF 1-29

CJC-1295 (no DAC) / GRF 1-29

Short-acting GHRH analog used in research protocols for pulsatile GH signaling.

XRedditFacebook
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
Studies cited
2
Research grade
S
Community score
135

Trend index

Trackers
3,000

Overview

About Mod GRF 1-29

Short-acting GHRH analog used in research protocols for pulsatile GH signaling.

Category
GH Secretagogues
Regulatory status
Research Only
Also known as
CJC-1295 (no DAC) / GRF 1-29
Self-reports
27

Community

What 27 users report

27 community reports

Positive 98% · Neutral 2% · Negative 0%

Most reported benefits

Sleep
160

Most reported side effects

Headache
4

Dose distribution

Median: 100–200 mcg · Most common: 100–200 mcg

0–25
0
25–50
0
50–100
0
100–200
100
200–400
60
400–600
0
600–1000
0
1000–2000
0
2000+
0

How repeat users are trending

Among repeat reporters, 91% said they felt similar to their last entry, 9% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 170 days · Based on 23 repeat reporters

Research

Cited research (1)

Help

Frequently asked

What do PeptIQ users report about Mod GRF 1-29?

This page summarizes 27 anonymized self-reports from PeptIQ users who track Mod GRF 1-29, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.

What research is cited for Mod GRF 1-29?

1 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.

Is Mod GRF 1-29 safe to use?

This wiki does not assess safety or recommend use. Mod GRF 1-29 is listed as Research Only. Consult a licensed clinician for personal medical decisions.

What are the purported benefits and uses of Mod GRF 1-29?

Research, primarily in animal models, suggests Mod GRF 1-29 may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.

Source

What is the legal status of Mod GRF 1-29?

Mod GRF 1-29 is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Mod GRF 1-29 as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.

Source

What are the known or theoretical side effects and risks of Mod GRF 1-29?

The safety and effectiveness of Mod GRF 1-29 have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.

Source

What is the current state of research on Mod GRF 1-29?

While there are over 200 published studies on Mod GRF 1-29, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.

Source